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Abstract 
As research continues in the field of coronary artery disease, more information is revealed about various 
etiological factors. Emerging lipoprotein risk factors have been identified and are now starting to surface 
as instrumental in the cause and prevention of coronary artery disease. In order to conduct comprehensive 
cholesterol screening programs and counseling sessions a health professional must have a thorough 
understanding of lipid metabolism. Recent changes in cholesterol guidelines make it necessary to have a 
review that addresses the specifics of lipid management. A health professional needs an appropriate 
knowledge base to be able to understand a major coronary artery disease risk factor and thereby more 
effectively educate the public about lipid management and coronary artery disease risk reduction. 
Therefore, the purpose of this article is to review the role of cholesterol in both normal physiological 
functioning and disease causation and to examine the research concerning new emerging cholesterol risk 
factors. 
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Cholesterol Screening and the Health 
Professional 
Recommendations by the National Cholesterol 
Education Program (NCEP) suggest that all 
Americans over the age of twenty should have 
their cholesterol concentrations measured 
(National Heart, Lung, and Blood Institute 
[NHLBI], 2003). An estimated 70.8% of the US 
population twenty years and older had 
participated in cholesterol screening at least 
once by the year 2000. This is a substantial 
increase from the mid-1980s when 35% had 
been screened at least once (Brown, Giles, 
Greenlund, & Croft, 2001). A number of health 
education programs have an emphasis on 
cholesterol screening followed by counseling 
with a health professional. Through these 
screenings health professionals can have a 
significant impact on cardiovascular disease 
outcomes by being involved in primary and 
secondary prevention, raising awareness, and 
successfully referring participants to physicians 
for further testing (Bowden, Kingery, & 
Brizzolara, 1999; Muratova, Islam, Demerath, 
Minor, & Neal 2001). In order to conduct 
comprehensive cholesterol screening programs 
and counseling sessions, health professionals 
must have a thorough understanding of coronary 
artery disease (CAD) risk factors which includes 
lipid metabolism (Ostwald, Weiss-Farnan, & 
Monson, 1990). Since the most important aspect 
of cholesterol screening is the action the 
participants take after receiving their screening 
results (Garber & Browner, 1997), having 
accurate and up-to-date information on the role 
of cholesterol in CAD enables health 
professionals to effectively develop and 
implement prevention programs, educate the 
public, and make referrals (Sullivan, 2002). 
Recent changes in cholesterol guidelines make it 
necessary to have a review that addresses the 
specifics of lipid management and CAD 
prevention. Therefore, the purpose of this paper 
is to review the role of cholesterol in both 
normal physiological functioning and disease 
causation and to examine the latest research 
concerning the new emerging cholesterol risk 
factors of CAD. 
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Overview 
According to the American Heart Association 
[AHA] (2002), more Americans die from CAD 
every year than the next five leading causes of 
death combined. One in every 2.5 deaths in the 
year 2000 was from heart disease (Kohlman-
Trigoboff, 2005). Though there has been a 
decrease in mortality rate in the US, CAD has 
become a leading cause of global mortality, 
accounting for almost 17 million deaths annually 
with nearly 80% of mortality and disease burden 
occurring in developing countries (Smith, 
Jackson, Pearson, Fuster, Yusuf, & Faergeman, 
et al., 2004). 
 
The etiology of CAD is multi-factorial, 
involving numerous factors including genetics, 
diet, and environment with several risk factors 
significantly increasing an individual’s 
susceptibility to the disease. These risk factors 
include cigarette smoking, obesity, sedentary 
lifestyle, dietary habits, homocysteine, high 
blood pressure, high blood cholesterol and 
others. However, much of the research into 
CAD, which has being quite extensive and 
spanning a number of decades, has focused on 
the general relationship between plasma lipids 
and CAD (Gotto, 1997; Kannel, Castelli, 
Gordon, & McNamara, 1971; McGee, Reed, 
Stemmerman, Rhoads, Yano, & Feinlab, 1985; 
NCEP, 2002; NIH, 1989a;). Researchers have 
suggested that approximately twenty-five 
percent of the adult population ages twenty and 
older has blood cholesterol levels that are 
considered high (National Institutes of Health 
[NIH], 1989b). In addition, researchers have 
demonstrated that a total cholesterol level in the 
“high” category (>200 mg/dL) accompanied 
with high blood pressure (>130/85) increases an 
individual’s risk of coronary heart disease by a 
factor of six (NIH, 1989b). Therefore, 
establishing specific guidelines for cholesterol 
levels is both important and necessary to 
enhance the health of individuals. 
 
Lipoprotein metabolism is a process that is not 
completely understood with fragmentary 
findings (Tulenka & Sumner, 2002). Attempting 
to have a clearer understanding of the 
relationship between cholesterol levels and 
CAD, individuals who have abnormal lipid 
levels can make the lifestyle changes necessary 
to reduce the risk of CAD and its associated 
complications. Similarly, adequately informed 
health professionals are better able to educate 
the public about cholesterol and heart disease 
and more equipped to implement effective 
health intervention programs. 
 
Cholesterol and Cardiovascular Disease 
Etiology 
Understanding the pathophysiology of CAD in 
population studies underlie the vital role of 
cholesterol metabolism. Protective mechanisms 
of the endothelium are evident in reverse 
cholesterol transport performed by high-density 
lipoprotein (HDL) and conversely low-density 
lipoprotein (LDL), specifically small, dense 
LDL, may penetrate the subendothelial space if 
concentrations are high in the plasma.  
Penetration of the endothelial space can cause 
acute and chronic endothelial damage, leading to 
CAD. Because movement into the arterial wall 
is likely driven by diffusion, hyper-
cholesterolemia increases the infiltration of 
cholesterol into the endothelial space (Bowden, 
2001; Wada & Karino, 1999). In response to this 
accumulation of cholesterol, macrophages 
respond to inflammatory markers from 
inflammatory cells, cytokines, growth factors 
and cellular responses (Sullivan, 2002) and 
absorb the cholesterol resulting in the formation 
of foam cells. Formations of foam cells are 
critical in the development of plaque in the 
endothelium (Ockene & Ockene, 1992). As the 
CAD progresses, lesions may begin to cause 
chronic injury to the endothelium. This process 
results in a positive-feedback cycle due to 
cytokine release that sends even more 
macrophages to the area, resulting in more foam 
cells, and eventually results in stenosis and 
occlusion of blood flow. Fatty streaks are first 
evident in this disease process followed by 
fibrous plaques that can develop necrotic cores 
which develop fissures leading to plague 
rupture. Hyperlipidemic concentrations also 
increase platelet aggregability, which attenuate 
the severity of the thrombotic process (Sullivan, 
2002). Therefore, cholesterol metabolism plays a 
significant role in the development of plaque, 
stenosis, and eventually, myocardial infarction. 
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Total Cholesterol 
Historically, total cholesterol concentration was 
used to assess an individual’s risk of CAD 
(Bowden & Kingery, 2004). Because cholesterol 
contributes to the buildup of atherosclerotic 
plaques, an individual’s blood cholesterol 
concentration could be a way to measure risk for 
heart disease. Clinical studies are consistent in 
supporting the projection that for serum 
cholesterol levels in the 250-300 mg/dl range, 
each 1% reduction in serum cholesterol level 
reduces CAD rates by approximately 2% (NIH, 
1989a). However, the degree of stenosis and 
CAD varies between individuals with the same 
total cholesterol and other lipid levels (Bowden, 
Kingery, Rust, 2004, Kmietowicz, 1998; 
Telenko & Sumner, 2002). Total cholesterol 
tends to reflect average dietary habits that affect 
LDL, and can reasonably provide an assessment 
of CVD risk between participants. Yet, the 
differences in risk between individuals can be 
strongly influenced by many additional factors. 
Therefore the measurement of total cholesterol 
alone cannot adequately reflect individual risk of 
CAD (NIH, 2002) and should rarely be used as 
the sole lipid measure in cholesterol screenings.  
Other studies have also demonstrated the 
process of heart disease to consist of many 
factors that are independent of total cholesterol 
(Katerndahl & Lawler, 1999). These other risk 
factors fall into two three broad categories, 
consisting of blood markers, behavior, and 
biology. New blood tests that identify increased 
cardiovascular risk include various subfractions 
of cholesterol. Many of these new markers relate 
to the physiological functions of cholesterol and 
the interaction between these markers and the 
cholesterol in the periphery. 
 
The generally accepted ranges for total 
cholesterol levels (NIH, 2002) consist of 
desirable (<200mg/dL), borderline high (200-
239mg/dL), and high (≥240mg/dL). If a 
patient’s cholesterol level is in the high 
category, a LDL cholesterol measure should be 
performed. If the patient is in the borderline high 
range, another total cholesterol measurement 
should be taken within eight weeks and the 
average of the two readings used to guide future 
decisions (NIH, 2002). 
 
Cholesterol Subfractions 
LDL cholesterol accounts for 60-75% of the 
total serum cholesterol and is the terminal end of 
in the pathway of lipoprotein metabolism called 
cholesterol transport. Numerous epidemio-
logical, physiological, and animal models have 
linked high LDL levels to CAD (American 
Heart Association, 2004; Assman, Cullen & 
Schulte, 1998; NIH, 1989a; Smith et al., 2004; 
Stone, 2005). High levels of LDL cholesterol are 
able to penetrate the porous endothelium of 
arteries and begin to accumulate if plasma 
concentrations are abnormal. This natural plaque 
is eventually converted to unstable plaque 
increasing the likelihood of rupture and possible 
thrombosis (NIH, 2002). Accordingly, the 
greatest absolute diminution of risk can be 
achieved by the reduction of LDL which may 
directly lower platelet aggregation, vascular 
reactivity, and lower cytokine release leading to 
a further reduction in risk for myocardial 
infarction (Sullivan, 2002). In fact, when 
elevated LDL levels are combined with 
comorbidity factors of smoking and 
hypertension, this complex explains over 90% of 
myocardial infarction cases occurring in middle 
age (Wilhelmsen, 1997). The landmark 
INTERHEART data suggests that 90% of risk 
comes from combination of abnormal levels of 
apolipoproteins found in LDL and smoking. 
LDL contains ApoB-100 which has been linked 
to atherogenesis (Yusef, Hawken, Ounpuu, 
Dans, Avesum, Lanas et al., 2004). Finally, it 
should be noted that although LDL lowering 
therapy is believe to offer the greatest benefit for 
CAD risk reduction, LDL alone is insufficient to 
predict CAD incidence and risk stratification.  
The best risk prediction strategy requires 
measurement of other cholesterol components 
and particle size and concentration (Wald, Law, 
Watt, Wu et al., 1994). 
 
LDL ranges in size from the largest and least 
dense (LDL1), intermediate density and size 
(LDL2) to the smallest and most dense (LDL3). 
The ATP-III report states that small LDL 
particles are formed in large part, although not 
exclusively, as a response to elevation of 
triglycerides via the production of very-low 
density lipoproteins (VLDL) and specifically 
VLDL1 (Malloy & Kane, 2001; NIH, 2002). 
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The presence of small, dense LDL particles is 
associated with more than a three-fold increase 
in the risk of CAD and is independent of LDL 
levels (Austin, Breslow, Hennekens, Buring, 
Willett, & Kraus, 1988). Tulenka & Sumner 
(2002) further suggest that not all LDL particles 
are the same and that variations in disease 
outcomes may by attributable to differences in 
particle size and number even when LDL levels 
are the same between patients. The authors of 
the Physicians Health Study demonstrated that 
each decrease of eight angstroms in LDL peak 
particle size was associated with a significant 
38% increase in the seven-year risk of 
myocardial infarction after adjustment for age 
and smoking status (Lemarche, Lemieux, & 
Depres, 1999). 
 
The correlation between particle size and CAD 
may exist because of the physiological 
properties of smaller particles. Researchers 
suggests smaller and denser LDL particles are 
more susceptible to in vitro oxidation and have 
been shown to be degraded less rapidly (Hsueh 
& Law, 1998). In addition, smaller particles 
diffuse more easily into the sub-endothelial 
space in the periphery. A stronger diffusion 
gradient would push more particles into the 
arterial wall, attract more macrophages, and 
develop more foam cells. 
 
Using gel electrophoresis, previous studies have 
computed and investigated both LDL peak 
particle size and the mean LDL particle size 
(Hsueh & Law, 1998). Mean LDL particle size 
is determined by computing the relative 
abundance of each of the LDL subclasses within 
one individual through a densitometric scan 
(Hsueh & Law, 1998; Lemarche et al., 1999). 
The results of these studies have led to the 
development of two different categories of LDL 
classification that rely on both peak particle size 
and LDL subclass distribution (Tulenko & 
Sumner, 2002). These two designations are 
Phenotype A and Phenotype B. Phenotype A 
consists of a predominance of LDL particles of 
>25.5 nanometers and Phenotype B is defined as 
the predominance of small LDL particles with 
diameters <25.5 nanometers. (Lemarche et al., 
1999). Researchers continue to investigate any 
relationship between Phenotype B and CAD and 
future findings may include either mean or peak 
particle size recommendations. 
 
However, Cromwell and Otvos (2004) believe it 
is not clear that small LDL particles are more 
atherogenic than large ones simply because 
individuals with small LDL particles also have a 
higher LDL particle number.   The authors 
further state that LDL particle number measured 
by nuclear magnetic resonance has consistently 
been shown to be a strong, independent 
predictor of CAD.  In other words, small dense 
particles may have been found to be more 
atherogenic due to a higher number of particles 
that are typically associated with small dense 
particles.  Also, the combination of the two 
(high particle number, and small dense particles) 
may place individuals at more risk than either 
risk factor alone. 
 
Previous studies have identified a LDL 
cholesterol “disconnect” between LDL 
concentration and the number or size of LDL 
particles among patients with low levels of LDL 
cholesterol (Otvos, Jeyarajah, & Cromwell, 
2002). The term disconnect suggests a differing 
risk profile depending on the type of LDL 
cholesterol measure that is used. Typically many 
individuals who are considered to have normal 
levels of LDL cholesterol will screen abnormal 
using phenotype designation.  This difference, or 
disconnect, may help to explain why myocardial 
infarction can occur in some people who have 
normal cholesterol and/or LDL levels. 
Furthermore, since cholesterol is carried via 
lipoproteins within the blood in spherical 
particles, between any two individuals there can 
be tremendous differences in both the number, 
size and composition of these particles (Garvey 
2003; Tulenko & Sumner, 2002). The 
implication of this disconnect is that CAD risk 
between two patients with identical LDL particle 
number and particle size would be the same, 
despite differing LDL concentration values 
(Garvey, 2003; Otvos et al., 2002; Tulenko & 
Sumner, 2002). 
 
The ATP-III (NCEP) report establishes the 
following ranges for LDL cholesterol levels: 
optimal (<100mg/dL), near optimal/above 
optimal (100-129 mg/dL), borderline high (130-
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159 mg/dL), high (160-189 mg/dL), and very 
high (≥190 mg/dL) (NIH, 2002). When risk is 
very high (two or more additional risk factors of 
existing heart disease), an LDL goal of <70 
mg/dL is a therapeutic option, but lifestyle 
changes should still be pursued. This therapeutic 
option extends also to patients at very high risk 
who have a baseline LDL <100 mg/dL (Grundy 
et al., 2004). 
 
 The metabolic balance of lipoproteins which is 
both vital and dangerous also uses reverse 
cholesterol transport to lower cholesterol in the 
periphery (Trigatti, 2005). HDL is synthesized 
by intestinal mucosal cells and the liver. It 
contains a small amount of phospholipids and 
ApoA1 (Tulenko & Sumner, 2002). Research 
has consistently identified an inverse 
relationship between HDL levels and CAD 
incidence.  The mechanism for this relationship 
is still unclear, leading some researchers to 
suggest that low HDL levels are simply a marker 
for other lipid abnormalities.  While the role of 
decreased HDL levels in atherosclerosis is still 
vague, it is considered an independent risk factor 
for CAD (NIH, 2002). It also has been identified 
as the greatest predictor, along with ApoA1 as 
the most important risk factor in patients with 
existing CAD (Bolibar, von Eckardstein, 
Assman, &Thompson, 2000; Devroey, 2004). 
HDL absorbs cholesterol in peripheral cells 
which enter the core of the cell through the 
action of lecithin-cholesterol acyltransferase. 
Inclusion of HDL in risk assessment can greatly 
enhance risk stratification (Kannel & Wilson, 
1992). 
 
Research scientists have also demonstrated that 
HDL has at least three distinct subclasses based 
on particle size. Different subclasses include 
nascent HDL, HDL2, and HDL3 with nascent 
HDL being the smaller and more dense followed 
by HDL3 and HDL2. One study found gender 
differences were most pronounced for large 
HDL, with women having a twofold higher (8 
vs. 4 micromole/L) concentration of large HDL 
particles than men. Additionally, the observed 
differences in males and females large HDL 
particle size also decreased with age (Freedman 
et al., 2004). The authors of a similar study 
found that the antioxidative activity of large 
HDL was significantly higher than that of small 
HDL (Kontush, Chantepie, & Chapman, 2003). 
Numerous small studies suggest greater 
predictive power for each of the HDL 
components including the observation that large 
HDL particles are more cardioprotective. All 
subclasses of HDL have been demonstrated to 
have a role in reverse cholesterol transport, but 
HDL2 seems to have the most protective effect, 
with recent evidence suggesting that HDL3 may 
play a role in LDL oxidation that is just as vital 
(Yoshikawa, Sakuma, Hibino, Sato, & Fujinami, 
1997). Finally HDL seems to have an 
antioxidant, anti-inflammatory, anti-adhesive, 
anti-aggregatory, and profibinolytic effect that 
aids in the control of CAD beyond reverse 
cholesterol transport mechanisms (Tulenko & 
Sumner, 2002). 
 
The ATP-III recommended ranges for HDL are 
low (<40 mg/dL) and high (>60 mg/dL).  This is 
a significant change as previous reports also set 
recommended levels for HDL, but the low 
designation was set at less than 35 mg/dL (NIH, 
2002). Additionally, the third report has 
removed specific HDL levels for men and 
women, and made one recommendation of 
greater than 50 mg/dL. 
 
Another subclass of lipoprotein is VLDL which 
can be divided into VLDL1 (large and less 
dense), VLDL2 (smaller and more dense), and 
VLDL3 (smallest and most dense). 
Hypertriglyceridemia is associated with an 
excess of VLDL1 while hypercholesterolemia is 
associated with excess VLDL2. VLDL is 
triglyceride rich and contains C-II, ApoE, and 
ApoB-100.  Lipoprotein lipase reduces the size 
of VLDL through the release of triglyceride 
creating a smaller, dense and more cholesterol 
rich lipoprotein.  About two-thirds of VLDL 
passes down the lipoprotein metabolism cascade 
terminating as LDL (Tulenka & Sumner, 2002). 
VLDL1 is a key component is what has been 
called the atherogenic lipoprotein profile, which 
when combined with small dense LDL, and low 
HDL, it is theorized to be a significant lipid risk 
factor for CAD (Austin et al., 1988). Most 
triglycerides are consumed from food, but 
during times of decreased caloric intake, the 
liver produces triglyceride endogenously 
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(Kwiterovich, 1989). The ATP-III reports that 
VLDL levels should be less than 31 mg/dL. 
 
Triglycerides are a primary source of energy and 
their levels in the periphery vary significantly.  
Historically, it has been understood that high 
VLDL and triglyceride levels were the result of 
elevated total cholesterol and lower levels of 
HDL cholesterol (Ginsberg, 1999; Tulenk & 
Sumner, 2002), but recent studies have shifted 
elevated triglyceride levels from an association 
with CAD to an independent predictor of the 
disease (Cullen 2000; Ginsberg, 1999; NIH, 
2002; Malloy & Kane, 2001;). Furthermore, this 
independent relationship suggests some 
triglyceride-rich lipoproteins are atherogenic 
(Cullen 2000; NIH, 2002), meaning VLDL 
levels may prove to be a significant risk factor in 
the future. With hypertriglyceridemia, 
triglycerides are transferred from VLDL and 
chylomicrons (cholesterol molecules formed 
from dietary substrates) to LDL, leading 
primarily to small dense LDL particles and more 
CAD (Tulenko & Sumner, 2002). 
 
Triglycerides should be measured after fasting 
as non-fasting triglyceride and other 
postprandial measurements are difficult to 
homogenize and arduous to perform (Sullivan, 
2002). Finally, the authors of the ATP-III report 
set the classification of triglyceride in the 
following categories: Normal (<150 mg/dL), 
borderline high (150-199 mg/dL), high (200-
499mg/dL), and very high (≥500mg/dL). 
 
Chylomicrons are very similar in their structure 
to VLDL, but are released by the intestinal 
mucosa cells directly after consuming fat 
(Tulenka & Sumner, 2002). They are less dense 
due to their large size (100-500nm) and the 
amount of triglyceride that is transported in 
them. Chylomicrons are found in the blood and 
lymphatic fluid where they serve to transport fat 
from its port of entry in the intestine to the liver 
and to adipose tissue. They travel via the 
lymphatic system and their large size renders 
penetration of the endothelium improbable. 
Though chylomicrons are large and rich in 
triglyceride, they contain only a relatively small 
amount of protein (Hertz, 1999; Schumaker &, 
Lambertas, 1992). Once chylomicrons enter the 
blood. they acquire ApoE and ApoC-II. They 
gradually reduce in size by lipoprotein lipase 
which removes free-fatty acids from the 
triglyceride pool in the cell. Chylomicron 
remnants are reassembled with endogenous 
triglyceride and cholesterol esters to form 
VLDLs (Tulenka & Sumner, 2002). Partially 
degraded chylomicrons, called chylomicron 
remnants, probably carry some atherogenic 
potential (NIH, 2002). The ATP-III does not 
report guidelines for chylomicron levels. 
 
Recently, investigators from the INTERHEART 
study have demonstrated abnormal lipid levels, 
when combined with smoking, provide over 
90% of the risk associated with CAD (Yusef et 
al., 2004) and can be generalized globally. The 
authors of the study suggest that the 
ApoB/ApoA1 ratio was the most important risk 
factor for CAD. Previous research suggests that 
ApoB/ApoA1 has not warranted as much 
attention of other subfractions of cholesterol and 
therefore needs further study (Sullivan, 2002). 
The relative lack of familiarity among 
professionals regarding the importance of ApoB 
and ApoA1 levels has been a primary cause of 
ApoB measurement not prevailing over 
cholesterol levels as the basis for treatment 
guidelines. Finally, Sullivan (2002) suggests the 
stage has not been reached where ApoA1 levels 
can supersede HDL levels as the basis for 
treatment guidelines (Sullivan, 2002). 
INTERHEART is a landmark study that will 
likely reveal a greater role of the ApoB/ApoA1 
ratio in the progression of CAD. 
 
Conclusions 
As research continues in the field of CAD, more 
information is revealed about the etiology of the 
disease. New emerging risk factors have been 
identified and are now starting to surface as 
instrumental in the cause and prevention of 
CAD. The changes between each of the NCEP 
reports show an increased understanding into the 
nature of lipid interactions. Each report 
represents another step forward in unraveling the 
mechanisms behind atherosclerosis and CAD. 
Evidence suggests that LDL particle number and 
size may play an important role in disease 
progression. Additionally, triglyceride and 
VLDL have been identified as independent risk 
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factors for CAD. Finally, large HDL, 
specifically HDL2 and possibly HDL3 have 
been identified as important players in the 
reverse cholesterol transport. 
 
Health professionals need to have a thorough 
understanding of cholesterol and lipid 
management. Understanding risk factors such as 
cholesterol and being able to explain them in 
layman’s terms to clients, patients, and program 
participants is a necessary skill of health 
professionals. A very common approach by 
health professionals is a health fair involving 
some level of lipid screening and educational 
follow-up. By understanding the complex nature 
of CAD and lipid management, health 
professionals will be more effective in 
explaining the disease risk of participants, 
clients, and patients but will also understand the 
most appropriate time for physician referral 
and/or follow-up screening. 
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